OncoMatch/Clinical Trials/NCT05711615
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Is NCT05711615 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Pegylated Liposomal Doxorubicin Hydrochloride and Peposertib for metastatic dedifferentiated liposarcoma.
Treatment: Pegylated Liposomal Doxorubicin Hydrochloride · Peposertib — This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: dna-protein kinase (pk) inhibitor
Lab requirements
Blood counts
Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL; Hemoglobin >= 8 g/dL
Kidney function
Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 (per institutional estimate based on creatinine level)
Liver function
Total bilirubin <= 1.5 x institutional upper limit of normal (ULN); AST/ALT <= 3 x institutional ULN
Cardiac function
Patients with known history of clinically significant cardiac disease, or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Patients with left ventricular ejection fraction (LVEF) measurement below the institutional lower limit of normal (LLN) are excluded.
Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL; Total bilirubin <= 1.5 x institutional upper limit of normal (ULN); AST/ALT <= 3 x institutional ULN; Hemoglobin >= 8 g/dL; Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2; cardiac risk assessment NYHA class 2B or better; LVEF below LLN excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Los Angeles General Medical Center · Los Angeles, California
- USC / Norris Comprehensive Cancer Center · Los Angeles, California
- UCHealth University of Colorado Hospital · Aurora, Colorado
- University of Miami Miller School of Medicine-Sylvester Cancer Center · Miami, Florida
- University of Chicago Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify